Astrana Health Toekomstige groei

Future criteriumcontroles 5/6

De verwachting is dat Astrana Health de winst en omzet met respectievelijk 20.2% en 20.3% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 18.9% per jaar.

Belangrijke informatie

20.2%

Groei van de winst

18.9%

Groei van de winst per aandeel

Healthcare winstgroei	20.9%
Inkomstengroei	20.3%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Good
Laatst bijgewerkt	21 Nov 2024

Recente toekomstige groei-updates

Here's What Analysts Are Forecasting For Astrana Health, Inc. (NASDAQ:ASTH) After Its Third-Quarter Results

Nov 10

Recent updates

Astrana Health, Inc.'s (NASDAQ:ASTH) 33% Cheaper Price Remains In Tune With Earnings

Nov 18

Here's What Analysts Are Forecasting For Astrana Health, Inc. (NASDAQ:ASTH) After Its Third-Quarter Results

Nov 10

Astrana Health, Inc.'s (NASDAQ:ASTH) P/E Is Still On The Mark Following 25% Share Price Bounce

Oct 04

Is Astrana Health, Inc. (NASDAQ:ASTH) Trading At A 21% Discount?

Sep 26

Astrana Health's (NASDAQ:ASTH) Returns On Capital Not Reflecting Well On The Business

Sep 12

Is Astrana Health (NASDAQ:ASTH) Using Too Much Debt?

Aug 28

Astrana Health, Inc.'s (NASDAQ:ASTH) 29% Jump Shows Its Popularity With Investors

Aug 02

Is There Now An Opportunity In Astrana Health, Inc. (NASDAQ:ASTH)?

Jun 19

Capital Allocation Trends At Astrana Health (NASDAQ:ASTH) Aren't Ideal

Jun 02

Astrana Health, Inc. (NASDAQ:ASTH) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 09

Investors Still Waiting For A Pull Back In Astrana Health, Inc. (NASDAQ:ASTH)

Apr 15

At US$40.82, Is Apollo Medical Holdings, Inc. (NASDAQ:AMEH) Worth Looking At Closely?

Feb 25

Is Apollo Medical Holdings (NASDAQ:AMEH) Using Too Much Debt?

Feb 07

Apollo Medical Holdings: Good Company, Not Quite A Hold

Jan 17

With Apollo Medical Holdings, Inc. (NASDAQ:AMEH) It Looks Like You'll Get What You Pay For

Dec 27

Does This Valuation Of Apollo Medical Holdings, Inc. (NASDAQ:AMEH) Imply Investors Are Overpaying?

Apr 20

Is Apollo Medical Holdings (NASDAQ:AMEH) A Risky Investment?

Mar 21

Apollo Medical Holdings (NASDAQ:AMEH) Has More To Do To Multiply In Value Going Forward

Jan 06

Is Apollo Medical Holdings (NASDAQ:AMEH) Using Too Much Debt?

Dec 16

Apollo Medical to acquire Valley Oaks Medical Group

Oct 05

Winst- en omzetgroeiprognoses

NasdaqCM:ASTH - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	3,219	96	N/A	128	7
12/31/2025	2,600	72	84	108	11
12/31/2024	1,982	57	56	98	10
9/30/2024	1,722	62	70	82	N/A
6/30/2024	1,592	68	50	64	N/A
3/31/2024	1,454	62	52	66	N/A
12/31/2023	1,387	61	40	68	N/A
9/30/2023	1,328	45	112	134	N/A
6/30/2023	1,297	46	61	83	N/A
3/31/2023	1,218	45	46	66	N/A
12/31/2022	1,144	45	59	82	N/A
9/30/2022	1,045	58	-40	-15	N/A
6/30/2022	955	69	41	72	N/A
3/31/2022	861	70	48	84	N/A
12/31/2021	774	69	51	70	N/A
9/30/2021	756	70	63	80	N/A
6/30/2021	709	53	57	65	N/A
3/31/2021	698	47	64	65	N/A
12/31/2020	687	38	45	46	N/A
9/30/2020	689	35	52	52	N/A
6/30/2020	665	22	47	48	N/A
3/31/2020	630	18	7	8	N/A
12/31/2019	561	14	13	14	N/A
9/30/2019	488	4	3	4	N/A
6/30/2019	499	10	-11	-10	N/A
3/31/2019	492	9	16	17	N/A
12/31/2018	520	11	24	25	N/A
9/30/2018	506	28	46	47	N/A
6/30/2018	436	24	N/A	41	N/A
3/31/2018	395	24	N/A	35	N/A
12/31/2017	356	26	N/A	52	N/A
9/30/2017	336	13	N/A	44	N/A
6/30/2017	323	11	N/A	45	N/A
3/31/2017	317	12	N/A	47	N/A
12/31/2016	306	11	N/A	22	N/A
12/31/2015	313	13	N/A	32	N/A
12/31/2014	134	-1	N/A	16	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei ASTH ( 20.2% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van ASTH ( 20.2% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).

Hoge groeiwinsten: De winst van ASTH zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van ASTH ( 20.3% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van ASTH ( 20.3% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van ASTH naar verwachting over 3 jaar hoog zal zijn

Astrana Health Toekomstige groei

Future criteriumcontroles 5/6

Belangrijke informatie

Recente toekomstige groei-updates

Here's What Analysts Are Forecasting For Astrana Health, Inc. (NASDAQ:ASTH) After Its Third-Quarter Results

Price target increased by 7.8% to US$63.29

Consensus EPS estimates fall by 12%, revenue upgraded

Price target increased by 8.0% to US$60.00

Astrana Health, Inc. Reiterates Earnings Guidance for the Year Ending December 31, 2024

Price target increased by 8.7% to US$58.71

Recent updates

Astrana Health, Inc.'s (NASDAQ:ASTH) 33% Cheaper Price Remains In Tune With Earnings

Investor sentiment deteriorates as stock falls 30%

Now 26% undervalued after recent price drop

Astrana Health, Inc. (NasdaqCM:ASTH) agreed to acquire Prospect Health Plan, Inc. from Prospect Medical Holdings, Inc.

Here's What Analysts Are Forecasting For Astrana Health, Inc. (NASDAQ:ASTH) After Its Third-Quarter Results

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Astrana Health, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Now 20% undervalued

Astrana Health, Inc.'s (NASDAQ:ASTH) P/E Is Still On The Mark Following 25% Share Price Bounce

Price target increased by 7.8% to US$63.29

Is Astrana Health, Inc. (NASDAQ:ASTH) Trading At A 21% Discount?

Now 21% undervalued

Investor sentiment improves as stock rises 15%

Co-Founder & Vice Chairman exercised options to buy US$926k worth of stock.

Astrana Health's (NASDAQ:ASTH) Returns On Capital Not Reflecting Well On The Business

Is Astrana Health (NASDAQ:ASTH) Using Too Much Debt?

Independent Director exercised options and sold US$485k worth of stock

Consensus EPS estimates fall by 12%, revenue upgraded

Price target increased by 8.0% to US$60.00

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Astrana Health, Inc. Reiterates Earnings Guidance for the Year Ending December 31, 2024

Price target increased by 8.7% to US$58.71

Astrana Health, Inc.'s (NASDAQ:ASTH) 29% Jump Shows Its Popularity With Investors

Astrana Health, Inc. (NasdaqCM:ASTH) entered into Securities Purchase Agreement to acquire Heritage Physician Networks from Heritage Health Systems Inc.

Astrana Health, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Investor sentiment improves as stock rises 19%

Is There Now An Opportunity In Astrana Health, Inc. (NASDAQ:ASTH)?

Capital Allocation Trends At Astrana Health (NASDAQ:ASTH) Aren't Ideal

New minor risk - Shareholder dilution

Astrana Health, Inc. (NASDAQ:ASTH) First-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Astrana Health, Inc. Reiterates Earnings Guidance for the Year Ending December 31, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Astrana Health, Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Astrana Health, Inc. to Report Q1, 2024 Results on May 07, 2024

Astrana Health, Inc., Annual General Meeting, Jun 12, 2024

Astrana Health, Inc. Announces Redesignation of Albert Young from Chief Administrative Officer to A New Role as Senior Vice President of Health Affairs

Investors Still Waiting For A Pull Back In Astrana Health, Inc. (NASDAQ:ASTH)

New minor risk - Shareholder dilution

Astrana Health, Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

At US$40.82, Is Apollo Medical Holdings, Inc. (NASDAQ:AMEH) Worth Looking At Closely?

Is Apollo Medical Holdings (NASDAQ:AMEH) Using Too Much Debt?

Apollo Medical Holdings, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Apollo Medical Holdings, Inc. Announces Management Changes

Apollo Medical Holdings: Good Company, Not Quite A Hold

With Apollo Medical Holdings, Inc. (NASDAQ:AMEH) It Looks Like You'll Get What You Pay For

Investor sentiment improves as stock rises 16%

Third quarter 2023 earnings: EPS exceeds analyst expectations

Apollo Medical Holdings, Inc. (NasdaqCM:AMEH) announces an Equity Buyback for $100 million worth of its shares.

Apollo Medical Holdings, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Returns On Capital At Apollo Medical Holdings (NASDAQ:AMEH) Have Stalled

Should You Investigate Apollo Medical Holdings, Inc. (NASDAQ:AMEH) At US$30.62?

Apollo Medical Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Apollo Medical Holdings (NASDAQ:AMEH) Has A Pretty Healthy Balance Sheet

Now 20% undervalued

Apollo Medical Holdings, Inc. Reiterates Earnings Guidance for the Year Ending December 31, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Returns At Apollo Medical Holdings (NASDAQ:AMEH) Appear To Be Weighed Down

Apollo Medical Holdings, Inc. to Report Q2, 2023 Results on Aug 07, 2023

A Look At The Intrinsic Value Of Apollo Medical Holdings, Inc. (NASDAQ:AMEH)

Apollo Medical Holdings, Inc. (NasdaqCM:AMEH) entered into a definitive agreement to acquire Assets of Texas Independent Providers, LLC.

We Think Apollo Medical Holdings (NASDAQ:AMEH) Can Stay On Top Of Its Debt

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Apollo Medical Holdings, Inc. Provides Earnings Guidance for the Year 2023

Apollo Medical Holdings' (NASDAQ:AMEH) Returns On Capital Are Heading Higher

Does This Valuation Of Apollo Medical Holdings, Inc. (NASDAQ:AMEH) Imply Investors Are Overpaying?

Is Apollo Medical Holdings (NASDAQ:AMEH) A Risky Investment?

Investor sentiment improves as stock rises 16%

Full year 2022 earnings: EPS and revenues exceed analyst expectations